Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole SodiumCategory 1.1 Ne...

HONG KONG, 17 July 2013 – Sihuan Pharmaceutical Holdings Group Ltd. announced that Anaprazole Sodium, a Category 1.1 new drug received the Approval for Clinical Studies from the State Food and Drug Administration (“SFDA”) of the People’s Republic...

Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole SodiumCategory 1.1 New Drug Clinical Studies
2015-08-13
CFDA Granted Full Approval of Phase I/II/III Clinical Trials for Pirotinib, an Internally Developed Innovative Patented

On 7 August 2015, the China Food and Drug Administration (CFDA) has granted full approval of Phase I/II/III clinical trials of Pirotinib, the innovative patented oncology drug successfully developed b...

2015-08-06
Deutsche Bank Analyst Report--Sihuan Pharmaceutical

Deutsche Bank Analyst Report--Sihuan Pharmaceutical

2015-08-06
BOCM International- August 3rd Sihuan Teleconference Transcript

BOCM International- August 3rd Sihuan Teleconference Transcript

2015-08-03
Sihuan Pharmaceutical Announces 2014 Annual Results

Sihuan Pharmaceutical Announces 2014 Annual Results, Profit Attributable to Owners of the Company up 30.1%

2015-07-14
CFDA Accepts Application for Clinical Trial Approval for Sihuan Pharmaceutical’s Self-Developed Category 1.1 Innovative

At the end of June 2015, Shandong Xuanzhu Pharma Co., Ltd. (“Shandong XuanZhu”), the Group’s innovative drug research and development division has submitted an Investigational New Drug application ...

Total 9 Pages  First page  Page up  Page down  Last page

Select

  • 2015
  • 2014
  • 2013
  • 2012